Drug Database
Back to search

Netherlands· NL-5e68ab9c2a25

Senshio 60 mg filmomhulde tabletten

A ospemifene product containing ospemifeen, registered in Netherlands by Shionogi B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC G03XC05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedSenshio 60 mg filmomhulde tablettenATCG03XC05REGISTER NO.NL-5e68ab9c2a25PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ospemifeenAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ospemifene is registered in 11 of 19 countries.

Countries holding a registration under ATC G03XC05 (ospemifene), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search ospemifene products by name

Ospemifene · ATC G03XC05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
OSPEMIFEEN
Manufacturer
Shionogi B.V.
Country
Netherlands (NL)
ATC code
G03XC05
ATC class
Ospemifene
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/978

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

52 interactions on record for ospemifene.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ospemifene against other medicinesHow interaction checks work

Ospemifene · interactions on record

52 records

  • 7 severe
  • 45 moderate

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • FluconazoleJ02AC01severe
  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ospemifene in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ospemifene products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Senshio
  • Liechtenstein · Senshio
  • Norway · Senshio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/be7754a1-0a08-413a-87e4-ad933d69d2a7
GET /v1/drugs/be7754a1-0a08-413a-87e4-ad933d69d2a7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/senshio-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ospemifene",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113459",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "GLYCEROLTRIACETAAT (E 1518)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "MAÏSZETMEEL, GEPREGELATINEERD",
    "NATRIUMZETMEELGLYCOLAAT",
    "POVIDON K 25 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "OSPEMIFEEN"
  ],
  "leaflet_url": null,
  "authorised_at": "2015/01/19",
  "procedure_number": "EMEA/H/C/002780",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/978",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ospemifene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console